About 4586

Founded: 2002
Employees: 21
CEO: Yonehiro Matsumura
WebsiteView website: www.medrx.co.jp

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.

Recent 4586 News & Updates

New Risk • Aug 28

New minor risk - Shareholder dilution

The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (JP¥121m revenue, or US$758k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (JP¥4.44b market cap, or US$27.8m).

Recent updates

No updates

MedRx Co., Ltd Stock Price

4586 Share Price Performance

4586 Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

MedRx Co., Ltd Key Details

About 4586

Recent 4586 News & Updates

Here's Why We're Watching MedRx's (TSE:4586) Cash Burn Situation

New minor risk - Shareholder dilution

Second quarter 2026 earnings released: JP¥5.26 loss per share (vs JP¥3.94 loss in 2Q 2025)

Recent updates

MedRx Co., Ltd Competitors

Shionogi

Eisai

Kyowa Kirin

Ono Pharmaceutical